Skin and Connective Tissue Diseases

Symptoms and General Pathology

All Conditions

Alopecia

Alopecia Areata

Hypotrichosis

Hair Diseases

Skin Diseases

Pathological Conditions, Anatomical

Pharmaceutical Solutions

All Drugs and Chemicals

Herbal Medicinal Product, topical use by spray on the scalp

Placebo, topical use by spray on the scalp

The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours

CG 428 cutaneous solution

Placebo cutaneous solution

Khalil KZ ZAMAN

The aim of this trial is to compare the degree of efficacy, safety and tolerability of CG 428 cutaneous solution versus placebo on prevention of chemotherapy induced alopecia (CIA) in female patients with metastatic cancer treated with selected regimens inducing alopecia.

Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)

A Randomized, Double Blind, Single Center, Controlled Study to Compare the Efficacy, Safety and Tolerability of CG 428 Cutaneous Solution With Placebo on Alopecia in Cancer Female Patients Under Chemotherapy

Physical examination of the scalp: skin AEs, hair status (alopecia graded according to CTCAE v.4.03.)

CTCAE v. 4.03 : Common Toxicity Criteria for Adverse Event (skin toxicity)

Olsen's visual analog scale : visual aid for estimating percentage scalp hair loss.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)	NCT02919735	Alopecia	CG 428 cutaneou... Placebo cutaneo...	18 Years -	Legacy Healthcare SA
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)	NCT02919735	Alopecia	CG 428 cutaneou... Placebo cutaneo...	18 Years -	Legacy Healthcare SA

Spots Global Cancer Trial Database for placebo cutaneous solution